-DOCSTART- -X- O
The -X- _ O
early -X- _ O
manifestations -X- _ O
of -X- _ O
coccidioidomycosis -X- _ B-Intervention
( -X- _ I-Intervention
valley -X- _ I-Intervention
fever -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
similar -X- _ O
to -X- _ O
those -X- _ O
of -X- _ O
other -X- _ O
causes -X- _ O
of -X- _ O
community-acquired -X- _ O
pneumonia -X- _ O
( -X- _ O
CAP -X- _ O
) -X- _ O
. -X- _ O
Without -X- _ O
specific -X- _ O
etiologic -X- _ O
testing -X- _ O
, -X- _ O
the -X- _ O
true -X- _ O
frequency -X- _ O
of -X- _ O
valley -X- _ B-Intervention
fever -X- _ I-Intervention
may -X- _ O
be -X- _ O
underestimated -X- _ O
by -X- _ O
public -X- _ O
health -X- _ O
statistics. -X- _ O
Therefore -X- _ O
, -X- _ O
we -X- _ O
conducted -X- _ O
a -X- _ O
prospective -X- _ O
observational -X- _ O
study -X- _ O
of -X- _ O
adults -X- _ B-Patient
with -X- _ I-Patient
recent -X- _ I-Patient
onset -X- _ I-Patient
of -X- _ I-Patient
a -X- _ I-Patient
lower -X- _ I-Patient
respiratory -X- _ I-Patient
tract -X- _ I-Patient
syndrome. -X- _ I-Patient
Valley -X- _ B-Outcome
fever -X- _ I-Outcome
was -X- _ I-Outcome
serologically -X- _ I-Outcome
confirmed -X- _ I-Outcome
in -X- _ I-Outcome
16 -X- _ I-Outcome
( -X- _ I-Outcome
29 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
55 -X- _ I-Outcome
persons -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
16 -X- _ I-Outcome
% -X- _ I-Outcome
â€“ -X- _ I-Outcome
44 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Antimicrobial -X- _ I-Outcome
medications -X- _ I-Outcome
were -X- _ I-Outcome
used -X- _ I-Outcome
in -X- _ I-Outcome
81 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
persons -X- _ I-Outcome
with -X- _ I-Outcome
valley -X- _ I-Outcome
fever. -X- _ I-Outcome
Symptomatic -X- _ I-Outcome
differences -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
time -X- _ I-Outcome
of -X- _ I-Outcome
enrollment -X- _ I-Outcome
had -X- _ I-Outcome
insufficient -X- _ I-Outcome
predictive -X- _ I-Outcome
value -X- _ I-Outcome
for -X- _ I-Outcome
valley -X- _ I-Outcome
fever -X- _ I-Outcome
to -X- _ I-Outcome
guide -X- _ I-Outcome
clinicians -X- _ I-Outcome
without -X- _ I-Outcome
specific -X- _ I-Outcome
laboratory -X- _ I-Outcome
tests. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
valley -X- _ B-Outcome
fever -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
common -X- _ I-Outcome
cause -X- _ I-Outcome
of -X- _ I-Outcome
CAP -X- _ I-Outcome
after -X- _ O
exposure -X- _ O
in -X- _ O
a -X- _ O
disease-endemic -X- _ O
region. -X- _ O
If -X- _ O
CAP -X- _ O
develops -X- _ O
in -X- _ O
persons -X- _ O
who -X- _ O
travel -X- _ O
or -X- _ O
reside -X- _ O
in -X- _ O
Coccidioides-endemic -X- _ O
regions -X- _ O
, -X- _ O
diagnostic -X- _ O
evaluation -X- _ O
should -X- _ O
routinely -X- _ O
include -X- _ O
laboratory -X- _ O
evaluation -X- _ O
for -X- _ O
this -X- _ O
organism -X- _ O
. -X- _ O

